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2 TURI ET AL

Background: Wheeze and allergic sensitization are the strongest
early-life predictors of childhood asthma development; the
molecular origins of these early-life phenotypes are poorly
understood.
Objectives: We sought to identify metabolites associated with
early-life wheeze, allergic sensitization, and childhood asthma.
Methods: We conducted a nested case-control study using
Environmental influences on Child Health Outcomes Program
cohorts for discovery and independent replication. Wheeze and
allergic sensitization were defined by number of wheeze
episodes and positive specific IgE at age 1 year, respectively.
Asthma was defined as physician diagnosis of asthma at age 5 or
6 years. We used untargeted metabolomics, controlling for
observed and latent confounding factors, to assess associations
between the plasma metabolome and early-life wheeze, allergy,
and childhood asthma.
Results: Eighteen plasma metabolites were associated with firstyear wheeze in the discovery cohort (n 5 338). Z,Z
unconjugated bilirubin (UCB) and its related metabolites
exhibited a dose-response relationship with wheeze frequency;
UCB levels were 13% (b 5 0.87; 95% CI, 0.74-1.02) and 22%
(b 5 0.78; 95% CI, 0.68-0.91) lower in children with 1 to 3 and
41 wheeze episodes compared with those who never wheezed,
respectively. UCB levels were also associated with childhood
asthma (b 5 0.82; 95% CI, 0.68-0.98). Similar trends were
observed in 2 independent cohorts. UCB was significantly
negatively correlated with eicosanoid- and oxidative stress–
related metabolites. There were no significant associations
between metabolites and allergic sensitization.
Conclusions: We identified a novel inverse, dose-dependent
association between UCB and recurrent wheeze and childhood
asthma. Inflammatory lipid mediators and oxidative stress
byproducts inversely correlated with UCB, suggesting that UCB
modulates pathways critical to the development of early-life
recurrent wheeze and childhood asthma. (J Allergy Clin
Immunol 2021;nnn:nnn-nnn.)
Key words: Wheeze, asthma, metabolomics, bilirubin, lipid
mediators

Asthma is among the most common chronic syndromes in
children and results in substantial morbidity and annual health
care expenditure.1,2 The critical window for development of
childhood asthma can be traced back to vulnerable fetal and
early-life periods when the immune system and respiratory organs are still developing.3 Because wheeze and allergic sensitization are the strongest early-life predictors of childhood asthma
development,4 understanding the molecular origins of these
early-life and childhood phenotypes is critical for understanding
asthma pathogenesis.
Metabolomics is the analysis of low-molecular-weight compounds present in biological fluids and tissues, representing the
end products of cellular activity.5 Variation in the levels of these
metabolites reflects variation in genetic, epigenetic, microbiota,
and environmental exposures, and can provide insights into the
biochemical processes involved in the development of complex
childhood diseases, such as allergy and asthma.6 Although there
is some evidence that the early-life metabolome is associated
with lung function trajectories and the development of childhood
asthma and allergy,7-9 these studies had limited sample sizes,
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lacked replication, and are therefore not generalizable to other
populations. In addition, previous studies have not accounted
for unmeasured confounders, including unmeasured dietary and
environmental exposures, that can induce spurious associations,
erroneously bolster predictive performance, and bias estimates.10
To fill this gap in knowledge, we used untargeted metabolomics
to comprehensively profile the plasma metabolomes of more than
600 infants from 3 independent cohorts to identify and replicate
associations between infant metabolites and metabolic pathways,
and the phenotypes of wheeze and allergic sensitization at the first
year of life, and diagnosis of childhood asthma. We used an
approach robust to confounding, replicated results in independent
cohorts, and identified the potential mechanisms through which
these metabolites may protect against or potentiate these
phenotypes.

METHODS
Study population and design
This study was conducted using National Institute of Health Environmental
influences on Child Health Outcomes Program–funded Children’s Respiratory and Environmental Workgroup (CREW) consortium cohorts. CREW
consists of birth cohorts designed to understand the development of allergic
disease and asthma in children.11 Three CREW cohorts had available biospecimens and were included in this study: Infant Susceptibility to Pulmonary
Infections and Asthma following RSV Exposure (INSPIRE), Wisconsin Infant
Study Cohort (WISC), and Childhood Origins of Asthma study (COAST).
These 3 cohorts include a general population cohort (INSPIRE),12 a rural
cohort stratified by residence on a dairy farm (WISC),13 and a high-risk cohort
on the basis of parental history of asthma or allergies (COAST).14
The study was designed as a nested case-control study (see this article’s
Methods section in the Online Repository and Fig E1 in this article’s Online
Repository at www.jacionline.org). Cases were defined as those with wheeze
or allergic sensitization during the first year of life, and controls were defined
as those who never wheezed and were not sensitized to aeroallergens or food
during the first year of life. Cases and controls were matched on sex and age in
months at the time of sampling, with priority given to those who had both
plasma samples available for testing.

Outcome ascertainment
The diagnosis of wheeze at ages 1, 2, and 3 years was determined using
elements from the International Study of Asthma and Allergies in Childhood
questionnaire.15 Children who did not wheeze in the previous 12 months were
considered nonwheezers. Those who wheezed were categorized as follows on
the basis of standard International Study of Asthma and Allergies in Childhood categorical responses: 1 to 3 wheezing episodes in the previous 12
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months, and 41 wheezing episodes in the previous 12 months.16 Allergic
sensitization (yes/no) to common aeroallergens (cat, dog, mold mix, and house
dust mite mix) and food allergens (egg, milk, peanut) was defined on the basis
of positive specific IgE testing of plasma (>0.1 kUA/L) at age 1 year. Asthma
was defined as physician-diagnosed or parent-reported physician diagnosis of
asthma and/or physician-prescribed asthma medications including systemic
steroids for asthma exacerbations, at age 5 years (discovery cohort most recent
time point available) or 6 years (replication cohorts prespecified outcome time
point).

Untargeted metabolomics
Plasma samples were collected at age 1 year in all 3 cohorts. Additional
plasma samples were collected at age 3 years in the COAST cohort. Plasma
samples from INSPIRE were collected in EDTA anticoagulant, whereas
plasma samples from WISC and COAST were collected in heparin
anticoagulant. In total, we used 4 plasma metabolome data sets for this
study. Plasma metabolome data from the largest cohort at age 1 year,
INSPIRE, were used as the discovery data set, and the 3 data sets from the
WISC (at age 1 year) and COAST (at age 1 and 3 years) cohorts were used
for independent replication. Untargeted metabolic profiling and initial data
processing was performed by Metabolon, Inc, Research Traingle Park, NC.
We performed quality control (see Figs E2 and E3 in this article’s Online
Repository at www.jacionline.org) and used the Metabolomics Standard
Initiative to classify metabolites as annotated (level 1 or 2; identified or putatively annotated compounds), semi-annotated (level 3; putatively characterized compound classes), and nonannotated (level 4; unknown
compounds).17 We defined a metabolite’s abundance to be its LC-MS–determined peak area, which is proportional to concentration (see Fig E4 in this
article’s Online Repository at www.jacionline.org).18

Identifying and replicating wheeze- and
sensitization-associated metabolites
We determined the relationship between a phenotype (wheeze, sensitization, or asthma) and metabolite levels using the method described in
McKennan et al.10 In brief, we excluded metabolites with more than 50%
missing MS data, estimated latent factors that might confound the relationship
between the phenotype and metabolite levels, and used linear regression to
regress each metabolite’s log-abundance onto the wheeze, sensitization, or
asthma phenotypes, while accounting for age in months, sex (male/female),
daycare attendance (yes/no), breast-feeding status (exclusively breast-fed or
not in the first 6 months), and the latent factors. This uses inverse probability
weighting, with weights estimated using McKennan et al,10 to account for
nonignorable missing MS data. Q values were used to control the falsediscovery rate (FDR) at 20%. We further truncated the list of metabolites by
considering a metabolite for downstream analysis only if it was annotated,
its abundance was consistent with a wheeze-dose response, and if the direction
of the association replicated in WISC, the replication cohort with the largest
sample size. The wheeze-dose response, which is satisfied by metabolites
whose abundance is strictly increasing or decreasing in the ordered wheeze
variable, helped strengthen the biological underpinning of our findings. The
analyses performed in each replication data set were identical to that in the discovery data set.

Determining a metabolite’s correlation neighbors
We estimated the Pearson correlation between the log-abundances of a
selected metabolite and all other metabolites in the discovery data set
conditional on the phenotype of interest (cases and controls of sensitization or wheeze outcomes as defined in Outcome Ascertainment
section), age, sex, daycare attendance, diet, and other latent confounding
factors.10 The selected metabolite’s correlation neighbors were defined
using a stringent FDR threshold of 10% to mitigate confoundinginduced spurious associations that can arise in metabolomic correlation
networks.19

Cross-phenotype meta-analysis
We used the replication data to pool information across the phenotypes of
wheeze and asthma to explicitly test for replication. In brief, we tested the null
hypothesis that the Z,Z unconjugated bilirubin (UCB) levels were the same in
healthy controls (nonwheezers in previous year, nonwheezers in subsequent
years, or not diagnosed with asthma) and cases (those who wheezed in the
previous year, wheezed in subsequent years, or were diagnosed with childhood
asthma, respectively). The alternative hypothesis was that the directions of the
differences in UCB levels between healthy controls and any of the other 3
groups matched those directions of differences observed in the discovery data
set. The test statistic, which corrects for correlation between phenotypes and
estimates derived from data sets with overlapping participants, was designed
to be standard normal under the null hypothesis, and reflect the directions of
the aforementioned differences under the alternative hypothesis. Additional
details are provided in this article’s Online Repository at www.jacionline.org.

Leukotriene B4 mediation analysis
Because leukotriene B4 (LTB4) was observed in only 14% of the samples in
the discovery data set, we coded it as binary (present or absent) when assessing
its role in mediating UCB’s association with wheeze to circumvent statistical
issues that arise when treating nonignorable missing MS data as continuous.10
We assessed the effect of UCB on LTB4 levels and of LTB4 levels on wheeze
risk using standard and ordinal logistic regression, respectively. Additional details are provided in this article’s Online Repository at www.jacionline.org.

RESULTS
Population characteristics and metabolite
identification
Characteristics of the INSPIRE population and the 2 replication cohorts (WISC and COAST) have been previously published.12-14 Characteristics of the nested case-control sample used
in this study are summarized in Table I, and a detailed description
is provided in this article’s Online Repository at www.jacionline.
org. First-year wheeze was not associated with aeroallergen or
food sensitization (P 5.50 and .72) in the discovery data set, indicating insignificant overlap between the 2 phenotypes.
We identified 938 annotated and 265 nonannotated metabolites
in the INSPIRE 1-year plasma discovery data set, and between
1039 and 1321 total metabolites in each of the 4 additional data
sets. There was large (824 of 1512) overlap in metabolites
identified from INSPIRE, WISC, and COAST (first- and thirdyear) plasma samples (see Table E1 and Fig E5 in this article’s
Online Repository at www.jacionline.org). The metabolites M-1
(C17H20N2O5), M-2 (C17H20N2O5), and M-3 (C17H18N2O4)
were retrospectively semi-annotated (Metabolon, Inc) to be
bilirubin degradation products. (See Table E2 and Fig E6 in this
article’s Online Repository at www.jacionline.org. Fig E6 was
modified from Jasprova et al.20)
Identifying plasma metabolites associated with
allergic sensitization
No metabolites in the INSPIRE plasma data set were significantly correlated with aeroallergen sensitization at a 20% FDR.
However, INSPIRE children with sensitization to at least 1 food in
the first year of life had significantly increased plasma alpha-D-glucuronic acid than those without a food sensitization, and the direction of the association was replicated in the COAST 1-year plasma
data set (P < .05; see Fig E7 in this article’s Online Repository at
www.jacionline.org). Correlation analysis showed that alpha-Dglucuronic acid had 3 correlation neighbors (see Table E3 in this article’s Online Repository at www.jacionline.org).
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TABLE I. Nested case-control study sample characteristics in discovery and replication cohorts

Characteristic

Birth weight (g), median (IQR) {P 5 .74}
Gestational age (wk), median (IQR) {P 5 .15}
Maternal years of education (school), median (IQR)
Maternal education level {P 5 1.4 3 10217}
Did not graduate high school (HS)
Graduated HS, but no college
Attended college, but did not graduate
Graduated college
Missing
Sex {P 5 .60}
Male
Female
Race {P 5 5.3 3 10214}
White
Black
Other
Multirace
Maternal marital status {P 5 8.6 3 10211}
Single
Married
Divorced/separated
Missing
Child exclusively breast-fed for the first 6 mo {P 5 9.8 3 10213}
Yes
No
First-year daycare attendance {P 5 3.0 3 1024}
Yes
No
Maternal smoking during pregnancy {P 5 .0019}
Yes
No
Missing
Paternal asthma {P 5 6.0 3 1025}
Yes
No
Maternal asthma {P 5 8.1 3 1027}
Yes
No
Unknown
Missing
Maternal allergic rhinitis {P 5 8.8 3 10220}
Yes
No
Unknown
Missing
Maternal eczema {P 5 4.9 3 1028}
Yes
No
Missing
First-year wheeze {P 5 .035}
Never wheeze
1-3 wheezing episodes
41 wheezing episodes
Second-year wheeze {P 5 .49}
Never wheeze
1-3 wheezing episodes
41 wheezing episodes
Missing
Third-year wheeze {P 5 .81}
Never wheeze

Discovery cohort
(INSPIRE)

Replication cohort
(WISC)

EDTA
plasma (1 y)*

Heparin
plasma (1 y)

Heparin
plasma (1 y)

Heparin
plasma (3 y)

3433 (596)
39 (1)
14 (2)

3458 (621)
39 (2)
See below

3402 (667)
39 (3)
See below

3572 (702)
40 (2)
See below

31 (9)
76 (22)
87 (26)
144 (43)
0 (0)

0 (0)
13 (9)
13 (9)
113 (78)
6 (4)

0
4
12
49
2

186 (55)
152 (45)

74 (51)
71 (49)

37 (55)
30 (45)

72 (57)
55 (43)

228 (67)
77 (23)
14 (4)
19 (6)

137 (94)
4 (3)
4 (3)
0 (0)

63
0
1
3

115 (91)
5 (4)
1 (1)
6 (5)

135 (40)
196 (58)
7 (2)
0 (0)

8 (6)
128 (88)
4 (3)
5 (3)

NA
NA
NA
NA

NA
NA
NA
NA

134 (40)
204 (60)

48 (33)
97 (67)

6 (9)
61 (81)

6 (5)
121 (95)

122 (36)
216 (64)

65 (45)
80 (55)

36 (54)
31 (46)

69 (54)
58 (46)

46 (14)
292 (86)
0 (0)

6 (4)
134 (92)
5 (3)

2 (3)
17 (25)
48 (72)

9 (7)
23 (18)
95 (75)

61 (19)
259 (81)

16 (12)
120 (88)

19 (29)
47 (71)

42 (34)
82 (66)

75 (22)
263 (78)
0 (0)
0 (0)

32 (22)
107 (74)
1 (1)
5 (3)

21
45
0
1

(31)
(67)
(0)
(1)

59
67
0
1

(46)
(53)
(0)
(1)

86 (25)
252 (75)
0 (0)
0 (0)

23 (16)
112 (77)
4 (3)
6 (4)

29 (43)
24 (36)
7 (10)
7 (10)

74
39
13
6

(58)
(27)
(10)
(5)

67 (20)
271 (80)
0 (0)

29 (20)
110 (76)
6 (4)

28 (42)
23 (34)
16 (24)

43 (34)
62 (49)
22 (17)

226 (67)
46 (14)
66 (20)

112 (77)
32 (22)
1 (1)

52 (78)
11 (16)
4 (6)

94 (74)
30 (24)
3 (2)

245 (72)
58 (17)
35 (10)
0 (0)

89
28
1
27

53
11
3
0

93
27
7
0

269 (80)

78 (54)

(61)
(19)
(1)
(19)

Replication
cohort (COAST)

(0)
(6)
(18)
(73)
(3)

(94)
(0)
(1)
(4)

(79)
(16)
(4)
(0)

52 (78)

3
7
21
95
1

(2)
(6)
(17)
(75)
(1)

(73)
(21)
(6)
(0)

100 (79)
(Continued)
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TABLE I. (Continued)

Characteristic

Discovery cohort
(INSPIRE)

Replication cohort
(WISC)

EDTA
plasma (1 y)*

Heparin
plasma (1 y)

Heparin
plasma (1 y)

Heparin
plasma (3 y)

48 (14)
21 (6)
0 (0)

15 (10)
1 (1)
51 (35)

11 (16)
4 (6)
0 (0)

18 (14)
9 (7)
0 (0)

34 (27)
85 (67)
8 (6)

16 (24)
47 (70)
4 (6)

1-3 wheezing episodes
41 wheezing episodes
Missing
Asthma diagnosis {P 5 .87}
Yes
No
Missing

72 (21)
201 (59)
65 (19)

Replication
cohort (COAST)

Values are n (%) unless otherwise indicated. When appropriate, the P value for the feature’s heterogeneity across the 3 cohorts is given in curly parentheses.
*Some columns may add up to 99% or 101% because of rounding.

Discovery analyses identifying plasma metabolites
associated with wheeze
The abundances of 18 metabolites were significantly associated with first-year wheeze, which included 5 nonannotated, 3
semi-annotated, and 10 annotated metabolites (see Fig 1). The
semi-annotated bilirubin degradation products M-1 and M-2
were the metabolites most associated with wheeze (q 5
3.1 3 1024, 8.8 3 1024). M-1 and M-2, along with the third
semi-annotated bilirubin degradation product M-3, were highly
correlated with the significantly annotated metabolite UCB
(correlations 5 0.62, 0.57, and 0.87, P < 10216). The abundances
of all 3 of these bilirubin-related metabolites in children with 1 to
3 and 41 wheezing episodes were approximately the same as, and
substantially less than, their abundances in children without
wheeze, respectively (see Fig 2). However, because these metabolites were only semi-annotated, we used them to support, rather
than make standalone, biological conclusions.
The annotated metabolites that were significantly associated
with first-year wheeze included succinate, iminodiacetate, N(2-furoyl) glycine, 3-amino-2-piperidone, 5,6-dihydrouridine,
UCB, linoleoyl-linolenoyl-glycerol (18:2/18:3), pyroglutamine,
transurocanate, and cysteine-s-sulfate. Succinate, the most significant annotated metabolite, along with the marginally significant
metabolite aconitate (q 5 0.248), is involved in the citric acid cycle and has previously been observed in serum, urine, and exhaled
breath condensate metabolomes to predict mild adult and childhood asthma.21 Table E4 in this article’s Online Repository at
www.jacionline.org contains a complete list of all 18 metabolites
and their association with first-year wheeze.
Of the above-mentioned 10 annotated wheeze-associated
metabolites, 3 (3-amino-2-piperidone, 5,6-dihydrouridine, and
UCB) exhibited wheeze-dose responses. The abundances of
3-amino-2-piperidone and 5,6-dihydrouridine were higher in
children who wheezed than in those who did not wheeze (see
Table E4). However, the direction of these 2 associations failed to
replicate in the WISC cohort and were therefore excluded from
further analysis.
In contrast, UCB abundance was 13% lower (b1-3 5 0.87;
95% CI, 0.74-1.02) and 22% lower (b41 5 0.78; 95% CI,
0.68-0.91), on average, in children with 1 to 3 wheezing episodes
and 41 wheezing episodes compared with children with no
wheeze, respectively (see Fig 3, A). These results were recapitulated by UCB’s nearly significant photoisomer E,Z/Z,E unconjugated bilirubin (q 5 0.214; see Fig E8 in this article’s Online

Repository at www.jacionline.org); we observed a similar relationship between plasma UCB abundance and childhood asthma
(basthma5 0.82; 95% CI, 0.68-0.98; Fig 3, B), and the direction of
this association replicated in WISC. Therefore, UCB was the
only wheeze-associated metabolite that we considered for
further analysis.

Replication of the association between UCB and
wheeze
We used the replication data to assess the replicability of the
cross-sectional association between UCB levels and wheeze and,
given the relationship with future asthma in the discovery data,
further evaluate the effect of UCB on childhood asthma. Fig 3, A,
shows that the magnitude and direction of UCB’s cross-sectional
association with 41 wheezing episodes, and with the exception of
the data set with the smallest sample size, 1 to 3 wheezing episodes, were consistent in all replication data sets.
The results in Fig 3, B, show that the dependence of childhood asthma on UCB levels observed in the discovery data
replicate. The strong associations with asthma observed in
the year 1 and 3 COAST data sets (1-sided P 5 .00376 and
.0252) suggest that UCB also protects against future asthma.
Furthermore, the relationships between the semi-annotated
bilirubin degradation products M-1, M-2, and M-3 and both
wheeze and asthma mirrored all aforementioned associations
(see Fig 2), suggesting that this UCB-related pathway might
protect against wheeze and future asthma. We remark that
the correlation coefficients between estimates derived from
the year 1 and 3 COAST data sets, which contained overlapping individuals, are negligibly small, meaning it suffices to
treat estimates from all 4 data sets in Figs 2 and 3 as independent (for details, see this article’s Methods section in the Online Repository and Table E5 in this article’s Online
Repository at www.jacionline.org).
Lastly, we performed a cross-phenotype meta-analysis, which
pools information across replication cohorts and the phenotypes
wheeze and asthma, to explicitly test that the direction of the
associations between UCB levels and respiratory phenotypes
observed in the discovery data set replicate in the replication data
sets. The significant replication P value of .00638 is congruent
with the results in Fig 3, and suggests that the relationship between UCB levels and respiratory phenotypes is consistent across
populations.
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FIG 1. A Manhattan-like plot of F test P values from the discovery data set (INSPIRE) for the null hypothesis
that metabolite abundance in plasma is not dependent on wheeze status, where metabolites are grouped by
Metabolon, Inc–defined pathways. The dashed black line is the 20% FDR threshold, and points above and
below that line are labeled with diamonds and solid circles, respectively. UCB, its 3 semi-annotated putative
degradation products M-1, M-2 and M-3, as well as the 3 most significant annotated metabolites succinate,
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FIG 2. Estimates and 95% CIs for the expected abundance of the semi-annotated metabolites M-1, M-2, and
M-3 (chemical formulas C17H20N2O5, C17H20N2O5, and C17H18N2O4, respectively) in the plasma of children
who wheezed and have asthma with respect to those who did not wheeze and did not have asthma, respectively. The discovery cohort on the y-axis is in bold font, and the replication cohorts are in regular font; age is
given in years and n is the sample size.

Metabolites correlated with plasma UCB identify
potential mechanisms of action contributing to
early-life wheeze
To identify potential mechanisms through which UCB protects
against wheezing and asthma, we next sought to determine UCB’s
correlation neighbors. We identified 32 metabolites whose logabundances were significantly correlated with those of UCB’s (see

Fig 4). Besides the 2 semi-annotated bilirubin degradation products, the metabolites most positively correlated with UCB were
UCB’s photoisomers (E,Z/Z,E unconjugated bilirubin and E,E
unconjugated bilirubin) and biliverdin (an intermediate in the
catabolism of heme to UCB).22 Although UCB’s photoisomers
exhibited a wheeze-dose response, their associations with firstyear wheeze were not significant at a 20% FDR (see Fig E8).
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in years, and n is the sample size. Children in the WISC cohort were not yet old enough to define asthma.

Critical metabolites in the eicosanoid pathway, including
arachidonic acid (AA), were among the 15 metabolites negatively
correlated with UCB log-abundance. Given AA’s role in the
generation of eicosanoids, we next sought to determine whether
the only leukotriene we identified, LTB4, which was identified in
14% of the INSPIRE plasma samples and was most prevalent in
children who wheezed (P 5 .0180; see Fig 5, A), was related to
UCB abundance. Plasma UCB levels were associated with an increase in the odds of observing LTB4 (P 5 6.19 3 1024; see Fig 5,
B), which indicates that LTB4 may mediate the relationship between UCB and wheeze (see Fig 5, C). This statistically significant inverse relationship persisted even when we accounted for
differences in AA abundance. The only other eicosanoid we identified was 12-hydroxyeicosatetraenoic acid, which was observed
in 24% of the INSPIRE children. Although not statistically significant, there was an inverse relationship between UCB abundance
and the presence of 12-hydroxyeicosatetraenoic acid (see Fig E9
in this article’s Online Repository at www.jacionline.org).
The levels of plasma oxidative stress byproducts, such as
glycerophosphorylcholine and glycerophosphoethanolamine
(products of hypochlorous acid–induced plasmalogen degradation),23 as well as 5-oxoproline (a glutamic acid derivative),24
were inversely proportional to UCB abundance (see Table E6 in
this article’s Online Repository at www.jacionline.org).

DISCUSSION
To address the significant gaps in our understanding of the
molecular mechanisms underlying asthma development, we

studied the plasma metabolome profile of wheeze and allergic
sensitization, the 2 most significant early-life risk phenotypes for
asthma development, and childhood asthma. We applied a novel
and rigorous statistical approach that corrects for nonrandom
missing data and unobserved confounder factors,10 and using independent replication cohorts, replicated the direction and magnitude of the effects estimated in the discovery cohort.
We identified 18 plasma metabolites that were significantly
associated with first-year wheeze in discovery analysis. Among
the 10 annotated wheeze-associated metabolites, only UCB, a
byproduct of the normal catabolism of heme (see Fig E10 in this
article’s Online Repository at www.jacionline.org), exhibited a
replicable dose-response relationship with first-year wheeze, in
which higher plasma UCB levels were associated with fewer
wheezing episodes. The magnitude and direction of the association, as well as the dose response, were consistent across both
high-risk and non–high-risk cohorts. In addition, UCB levels
were protectively associated with childhood asthma, suggesting
that reduced UCB levels precede wheeze and asthma development. Lastly, and quite remarkably, the relationship between
wheeze and the 3 semi-annotated putative bilirubin degradation
products mirrored all of the aforementioned wheeze- and
asthma-UCB associations in all 4 data sets, indicating that derivatives of UCB may also aid in protecting against infant wheeze.
Our finding of a strong protective association of UCB and its
related metabolites with early-life wheeze and childhood asthma
is consistent with recent findings demonstrating that mildly
elevated bilirubin levels have a protective effect in respiratory
conditions.25,26 However, these observational studies were
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FIG 4. Histogram of the estimates for the conditional correlation between the log-abundances of UCB and
all other annotated metabolites with less than or equal to 50% missing data in the discovery data set. The
red and blue dashed lines are drawn at the correlation coefficients for metabolites corresponding to the 10%
FDR threshold, where metabolites to the left and right of those lines are defined as UCB’s correlation
neighbors. Abbreviated metabolites are glycerophosphorylcholine (GPC), glycerophosphoethanolamine
(GPE), lysophosphatidic acid 18:2* (LPA 18:2*), AA, and lysophos-phatidylcholine 18:2 (LPC 18:2).
Metabolites with an appended ‘‘*’’ are annotated metabolites with a Metabolomics Standard Initiative
level 2 (as opposed to level 1) identification.

conducted in adult populations and only considered total bilirubin, the sum of conjugated and unconjugated bilirubin concentration. Furthermore, no previous study had the resolution to
assess the relative impact of bilirubin’s isomers. Finally, this is
the first prospectively followed case-control study to find an association between bilirubin and risk of wheeze, and childhood
asthma, as well as the first to identify possible protective pathways through which bilirubin exerts its potential protective effect.
Contrary to our study, previous studies have demonstrated that
hyperbilirubinemia is associated with an increased risk for
developing asthma.27-31 However, these studies did not measure
bilirubin, and instead relied on a diagnosis of jaundice or a history
of phototherapy. Moreover, a recent study in infants measured total serum bilirubin (TSB) and found that there was no difference
_5.9 mg/dL)
between children with low to modest levels of TSB (<
and the highest levels of TSB (>18 mg/dL).32 Kuzniewicz et al33
was also only able to show that infants with TSB concentrations 2
to 3 times higher than those within the normal physiological range
are at an increased risk of developing asthma. In contrast, our
study measured unconjugated bilirubin and demonstrated that
higher concentrations, within the normal physiological range,
are associated with protection from asthma. This suggests that
if bilirubin is causal for asthma development, our and those results
from studies using upper extreme values suggest that the relationship between bilirubin levels and asthma risk follows a parabolic
relationship, where moderately low and extremely high levels
of bilirubin confer a greater risk for wheeze and asthma
development.

Murine models of asthma indicate that UCB has many antiinflammatory properties.34 However, the mechanisms by which
UCB is associated with reduced early-life wheeze and childhood
asthma in humans are unknown. We therefore used a correlation
analysis, along with a literature review, to posit pathways through
which UCB protects infants against wheeze and asthma (see
Fig 6). Notably, UCB levels were inversely proportional to those
of AA and LTB4, which is consistent with experimental results
that show that UCB inhibits many members of the secretory phospholipase A2 (sPLA2) family of enzymes (including sPLA2IIA)
in a dose-dependent manner at physiologically relevant concentrations.35,36 UCB’s inhibition of sPLA2IIA in vitro is even
irreversible and independent of substrate concentrations.35 The
observation that the significant inverse relationship between
UCB abundance and LTB4 presence persisted even after adjusting for AA abundance is congruent with UCB’s role as a
5-lipoxygenase inhibitor.36 The dependence of UCB’s inhibition
of sPLA2IIA and 5-lipoxygenase on UCB’s lipophilicity36 may
help explain why E,E unconjugated bilirubin levels are not as
closely associated with wheeze, because Z to E isomerization
of bilirubin reduces the intramolecular hydrogen bonding and
makes the molecule less lipophilic.37 These results suggest that
UCB may curb LTB4 production during respiratory infections,
which would decrease monocyte and leukocyte migration and
chemotaxis, as well as the production of neutrophil-generated superoxide in the airways.38,39
We also observed a significant negative correlation between
plasma UCB and lysophosphatidylcholine 18:2 and
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FIG 5. A, The relationship between year 1 wheeze frequency and LTB4 presence in the discovery cohort
(INSPIRE). B, UCB abundance in 1 year plasma as a function of whether or not LTB4 was identified in the
discovery cohort. ‘‘Wheezers’’ are defined as children with at least 1 wheeze episode in year 1. C, The
hypothesized relationship between UCB, LTB4, and wheeze, where red and blue edges indicate significant
inverse and direct relationships, respectively. The P values for edges y and x are those associated with Fig 5,
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quantify the associations plotted in Fig5, B, and A, respectively.

lysophosphatidic acid 18:2 levels. sPLA2s cleave membrane
phospholipids to produce lysophosphatidylcholine 18:2, which is
then hydrolyzed by autotaxin to produce lysophosphatidic acid
18:2.40,41 This suggests that UCB may protect against early-life
wheeze and childhood asthma in part by inhibiting the synthesis
of lysophosphatidic acids, which are upregulated in human bronchial lavage fluid during allergic inflammation42 and contribute to
airway injury, fibrosis, and vascular permeability.43
In addition, UCB acts as a potent source antioxidant by
inhibiting nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase,22 which is the source of many reactive oxygen
species. In addition to alleviating airway inflammation and hyperresponsiveness,44,45 this activity could account for the negative
correlations between plasma UCB levels and the hypochlorous
acid–induced plasmalogen degradation products glycerophosphorylcholine and glycerophosphoethanolamine, as well as the
oxidative stress indicator 5-oxoproline.
Given UCB’s possible role in protecting against early-life
wheeze and childhood asthma, it is therefore important to
understand the underlying sources of variation in blood UCB
levels, because this could be important for future therapeutic
interventions. UCB is excreted by the liver, where the first and
rate-limiting step is conjugation with glucuronic acid catalyzed
by uridine-diphosphoglucuronate glucuronosyltransferase 1A1
(UGT1A1).46,47 Individuals with slightly impaired UGT1A1

activity typically have elevated blood UCB levels, which is
commonly observed in individuals with a genetic variant in the
UGT1A1 gene (Gilbert’s syndrome).22 The enzyme UGT1A1
can also be inhibited by other metabolites. For example, retinol
(vitamin A) competitively inhibits UGT1A1 at physiologically
relevant intensities in vitro.48 The observation that plasma retinol
and UCB levels were significantly positively correlated in the
INSPIRE cohort may therefore be due to inhibition of the conjugation of UCB by retinol. Future studies addressing sources of
UCB variation in healthy children, including genetic, epigenetic,
and microbiome contributions, as well as diet and exposure histories, may aid in asthma prevention strategies.
Our study benefits from a large discovery cohort, as well as 2
independent replication cohorts. We were able to take advantage
of the infrastructure created by Environmental influences on
Child Health Outcomes and CREW birth cohorts, using harmonized data sets from birth cohorts that were specifically designed
to study wheeze and asthma. Another important strength is that
our analysis pipeline accounts for both latent confounding factors
and nonrandom missing mass spectrometry data, which helps
ensure our results are accurate and replicable.10 Limitations of
this observational study include uncertain causality in the association between metabolite levels and wheeze. However, the finding
of an inverse dose-response relationship of UCB levels and number of wheeze episodes and the fact that UCB levels are inversely
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FIG 6. A proposed mechanistic diagram by which UCB present in blood is associated with reduced risk of
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Metabolites with an appended ‘‘*’’ are annotated metabolites with a Metabolomics Standard Initiative level
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associated with future wheeze and childhood asthma support the
hypothesis that UCB may, in fact, protect against wheeze and
asthma development. Second, the plasma samples collected
from the discovery and replication data sets were collected using
different anticoagulants, the former with EDTA and the latter with
heparin. Although this could cause differences in metabolome results, we were encouraged by the degree of metabolite overlap
across cohorts and the robustness of the association between
UCB and wheeze despite differences in anticoagulant.

Conclusions
We identified a novel inverse association of unconjugated
bilirubin and its related metabolites with wheeze and childhood
asthma and mapped its likely mechanisms of action in silico.
These observations set the stage for mechanistic studies in other
experimental systems to confirm these relationships, and may
provide new therapeutic approaches to attenuate wheezing illnesses in infants, and potentially reduce the subsequent risk for
childhood asthma.
We acknowledge the Environmental influences on Child Health Outcomes
(ECHO) program and the Children’s Respiratory and Environmental Workgroup (CREW) cohort members. Please see list of members in this article’s

Online Repository at www.jacionline.org. We also thank all the families who
participated in this study.

Key messages
d

Protective association of unconjugated bilirubin and its
related metabolites on early-life wheeze and asthma.

d

Several inflammatory lipid mediators and oxidative stress
byproducts were inversely correlated with unconjugated
bilirubin, suggesting that unconjugated bilirubin modulates pathways critical to the development of early-life
wheeze phenotypes and asthma.

d

Results indicate that higher levels of bilirubin within the
normal physiological range are associated with salutary
effects on infant wheeze and asthma.
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